undamentalytics Newsletter
Sign in

Anixa Biosciences Inc income statement

In fiscal 2024, Anixa Biosciences Inc reported revenue of $210,000, up 0.0% on the year before, operating income of −$13.8m (a -6586.2% margin) and net income of −$12.6m, or −$0.39 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Oct 20102011Oct 20112012Oct 20122013Oct 20132014Oct 20142015Oct 20152016Oct 20162017Oct 20172018Oct 20182019Oct 20192021Oct 20212023Oct 20232024Oct 2024
Revenue1110490010100
Research and development332——12275656
Selling, general and administrative3338663476———
General and administrative——————————767
Operating income−5−5−4−8−5−1−5−6−14−12−13−11−14
Interest expense——011011—————
Income before tax−5−7−4−10−10−1−5−5−14−12———
Income tax—1———————————
Net income−5−7−4−10−10−1−5−5−14−12−13−10−13
Diluted EPS−$0.03−$1.00−$0.02−$0.05−$1.10−$16.00−$0.57−$0.58−$0.79−$0.59−$0.45−$0.32−$0.39
Diluted shares (average)—7m7m8m9m9m9m12m18m20m29m31m32m
EBITDA−5−5−4——−1−4−6−14−12———

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Anixa Biosciences Inc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Anixa Biosciences Inc.